Net Clinical Benefit of Prehospital Glycoprotein IIb/IIIa Inhibitors in Patients with ST-Elevation Myocardial Infarction and High Risk of Bleeding: Effect of Tirofiban in Patients at High Risk of Bleeding Using CRUSADE Bleeding Score

Author(s): 

Renicus S. Hermanides, MD1, Jan Paul Ottervanger, MD, PhD1, Jurrien M. ten Berg, MD, PhD2, 
A.T. Marcel Gosselink, MD, PhD1, Gert van Houwelingen, MD3, Jan-Henk E. Dambrink, MD, PhD1,
Pieter R. Stella, MD, PhD4, Christian Hamm, MD, PhD5, Arnoud W.J. van ’t Hof, MD, PhD1, on behalf of the On-TIME 2 Trial Investigators

References

  1. Van ’t Hof AWJ, Ten Berg JM, Heestermans AA, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet. 2008;372(9638):537-546.
  2. Ten Berg JM, van ’t Hof AWJ, Dill T, et al; Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. Effect of early, pre-hospital initiation of high-bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short and long-term clinical outcome. J Am Coll Cardiol. 2010;55(22):2446-2455.
  3. Hermanides RS, Ottervanger JP, Dambrink JHE, et al. Risk of bleeding after pre-hospital administration of high dose tirofiban for ST-elevation myocardial infarction. Int J Cardiol. 2010 Dec 29 (Epub ahead of print).
  4. Kinnaird TD, Satbile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol. 2003;92(8):930-935.
  5. Rao SV, O’Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005;96(9):1200-1206.
  6. Eikelboom JW, Metha SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114(8):774-782.
  7. Feit F, Voeltz MD, Attubato MJ, et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial. Am J Cardiol. 2007;100(9):1364-1369.
  8. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial. J Am Coll Cardiol. 2007;49(12):1362-1368.
  9. Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol. 2008;51(7):690-697.
  10. Van ’t Hof AWJ, Hamm C, Rasoul S, et al, on behalf of the On-TIME 2 investigators. Ongoing tirofiban in myocardial infarction evaluation (On-TIME) 2 trial: rationale and study design. EuroIntervention. 2007;3(3):371-380.
  11. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial — phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11(1):1-11.
  12. Cockgroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
  13. Subherwal S, Bach RG, Chen Ay, et al. Baseline risk of major bleeding in non-ST elevation myocardial infarction. Circulation. 2009;119(14):1873-1882.
  14. Goto S, Tamura N, Ishida H. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J Am Coll Cardiol. 2004;44(2):316-323.
  15. Montalescot G, Barragan P, Wittenberg O, et al; the ADMIRAL investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344(25):1895-1903.

 

  1. Ortolani P, Marzocchi A, Marrozzini C, et al. Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous coronary interventions: results of a registry study in an ST-elevation myocardial infarction network. Eur Heart J. 2009;30(1):33-43.
  2. Huber K, Holmes Jr DR, Van’t Hof AWJ, et al. Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. Eur Heart J. 2010;31(14):1708-1716.
  3. The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330(14):956-961.
  4. ESPRIT investigators. Enhanced suppression of the platelet IIb/IIIa receptor with integrillin therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000;356(9247):2037-2044.
  5. Ellis SG, Tendera M, de Belder MA, et al; FINESSE investigators. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med. 2008;358(21):2205-2217.
  6. Stone GW, Witzenbichler B, Guagliumi G, et al; HORIZONS-AMI trial investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358(21):2218-2230.
  7. Mehran R, Lansky AL, Witzenbichler B, et al; HORIZONS-AMI trial investigators. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009;374(9696):1149-1159.
  8. Lincoff AM, Bittl JA, Harrington RA, et al; REPLACE-2 investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289(7):853-863.
  9. Spencer FA, Moscucci M, Granger GB, et al; GRACE investigators. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation. 2007;116(24):2793-2801.
  10. Wang TY, Xiao L, Alexander KP, et al. Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. Circulation. 2008;118(21):2139-2145.
  11. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004;292(13):1555-1562.
  12. Rao SV, Eikelboom J, Steg PG, et al; Academic Bleeding Consensus Multidisciplinary Working Group. Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the Academic Bleeding Consensus (ABC) Multidisciplinary working group. Am Heart J. 2009;158(6):881-886.
  13. Verheugt FW, Steinhubl SR, Hamon M, et al. Incidence, prognostic impact, and influence of antithrombotic therapy on acces and nonaccess site bleeding in percutaneous coronary intervention. JACC Cardiovasc Interv. 2011;4(2):191-197.
  14. Alexander KP, Chen AY, Roe Mt, et al; CRUSADE investigators. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294(24):3108-3116.

 

  1. Abu-assi E, Gracia-Acuna JM, Ferreira-Gonzalez I, et al. Evaluating the performance of the can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines (CRUSADE) bleeding score in a contemporary Spanish cohort of patients with non-ST segment elevation acute myocardial infarction. Circulation. 2010;121(22):2419-2426.
  2. Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol. 2010;55(23):2556-2566.
  3. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium Early II trial substudy. Circulation. 2000;102(17):2031-2037.

_____________________________________________

From 1Isala klinieken, Department of Cardiology, Zwolle, The Netherlands, 2St. Antonius Ziekenhuis, Department of Cardiology, Nieuwegein, The Netherlands, 3Medisch Spectrum Twente, Department of Cardiology, Enschede, The Netherlands, 4Universitair Medisch Centrum Utrecht, Department of Cardiology, Utrecht, The Netherlands, and 5Kerckhoff-Klinik, Department of Cardiology, Bad Nauheim, Germany.
Disclosure: The authors have completed and returned the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr. van ’t Hof holds a research grant from Merck. Dr. Hamm holds an unrestricted grant for the ONTIME-2.
Manuscript submitted June 16, 2011, provisional acceptance given July 19, 2011, final version accepted December 1, 2011.
Address for correspondence: Arnoud W.J. van ’t Hof, MD, PhD, FESC, Isala klinieken, Department of Cardiology, Groot Wezenland 20, 8011 JW Zwolle, The Netherlands. Email: v.r.c.derks@isala.nl

Bookmark/Search this post with
image description image description Other Original Contribution Articles




  


  
Post new comment


  



 
 




 
 




 
 



  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
More information about formatting options





Image CAPTCHA

 
 
 
Enter the characters shown in the image.